Јапан - Енглески - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - lanthanum carbonate hydrate - white to grayish white tablets, diameter: 13 mm, thickness: 5.4 mm

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

pinewood healthcare - dantron; poloxamer 188 - oral suspension - 5mg/1ml ; 40mg/1ml

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

pinewood healthcare - poloxamer 188; dantron - oral suspension - 200mg/1ml ; 15mg/1ml

Малта - Енглески - Malta Medicines Authority

viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - chewable tablet - lanthanum 750 mg - all other therapeutic products

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dantrolene sodium hemiheptahydrate, quantity: 20 mg - injection, powder for - excipient ingredients: sodium hydroxide; mannitol - dantrium for injection is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crisis. it should be administered by intravenous injection as soon as the malignant hyperthermia reaction is recognised (i.e. tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilisation of anaesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever).

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

par pharmaceutical, inc. - dantrolene sodium (unii: 287m0347ev) (dantrolene - unii:f64qu97qcr) - dantrium intravenous is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. dantrium intravenous should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilization of anesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever). dantrium intravenous is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. none.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

procter and gamble pharmaceuticals - dantrolene sodium (unii: 287m0347ev) (dantrolene - unii:f64qu97qcr) - injection - dantrium intravenous is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. dantrium intravenous should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilization of anesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever). dantrium intravenous is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. none.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

par pharmaceutical, inc. - dantrolene sodium (unii: 287m0347ev) (dantrolene - unii:f64qu97qcr) - dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. if improvement occurs, it will ordinarily occur within the dosage titration (see dosage and administration ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrium. occasionally, subtle but meaningful improvement in spasticity may occur with dantrium therapy. in such instances, information regarding improvement should be solicited from the patient and those who are in c

Израел - Енглески - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - powder - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Израел - Енглески - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - powder - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.